TIDMORPH
RNS Number : 6763H
Open Orphan PLC
07 December 2020
7(th) December 2020
Open Orphan plc
("Open Orphan" or the "Company")
Venn Life Sciences contract wins
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials is pleased to announce its subsidiary Venn Life Sciences
("Venn") has been awarded two new contracts.
The first contract, which will commence immediately, is a
COVID-19 study for a European pharmaceutical company which involves
200 patients in 50 sites across 5 countries around the world.
Venn's Paris team will manage the randomisation and supply
management for this randomised, double-blind, placebo-controlled
Phase 2 Clinical Trial to evaluate the safety and efficacy of a
combination treatment of two drugs, and the best supportive care
for patients with moderate and severe COVID-19 in a hospitalised
setting.
Venn's team based in the Breda office, in the Netherlands has
also signed a contract with a European pharmaceutical company. The
contract will see Venn assist with project management, design and
implementation of new processes related to clinical development and
use its expertise to deliver process improvement. The contract,
which starts immediately, will run until December 2021 delivering
significant revenues for Venn.
This contract builds on Venn's existing relationship with this
European pharmaceutical company whom Venn currently provides a
variety of services to including IMPD writing, regulatory briefing
book writing, preclinical and clinical consultancy.
Cathal Friel, Executive Chairman, Open Orphan, said:
"As we come towards the end of 2020, it's wonderful to see all
the elements of the Open Orphan business are delivering substantial
revenues and both new contract wins and renewal of existing
long-term customer contracts. The merger and integration of Open
Orphan, Venn and hVIVO is very much now complete, and having become
profitable in Q4 2020, we now have a very valuable, fast growing
and secure business on our hands. Both Venn and hVIVO are
converting their substantial pipeline of work whilst providing a
high-quality service to their customers. The Paris team's contract
is a further demonstration of our work in the fight against
COVID-19 and the contract win by our Dutch Breda team shows how we
continue to generate repeat business through our expertise.
I am very excited by the momentum in the business and look
forward to providing further updates in the weeks and months ahead
of what is going to be a very exciting 2021".
ENDS
Interested in becoming a volunteer?
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . hVIVO welcomes volunteers to take part
in our clinical trials under expertly supervised conditions, to
further medical research, and help us to take the understanding of
respiratory illnesses to a new level. Volunteers are central to the
work that we do; our studies focus on testing new treatments on
real people, in a safe, controlled, clinical environment.
Further details on all aspects of our volunteer programs
including testimonials from previous volunteers can be found at
www.flucamp.com .
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser +44 (0)20 7614
and Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint +353 (0)1 679
Broker) 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is the world leader in the testing of
vaccines and antivirals through the use of human challenge clinical
trials. Conducted from Europe's only 24-bedroom quarantine clinic
with onsite virology lab, providing individually isolated rooms and
connected to our specialist laboratory facility. hVIVO's challenge
studies require healthy volunteers to take part, volunteers are
recruited through FluCamp, learn more at www.FluCamp.com . The
hVIVO facility offers highly specialised virology and immunology
laboratory services to support pre-clinical and clinical
respiratory drug, antiviral, and vaccine discovery and development.
Reliable laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUPGRWPUPUGCQ
(END) Dow Jones Newswires
December 07, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024